Caduceus Biotechnology Inc., in partnership with academic research institutions, has achieved a significant milestone in the development of an in vitro diagnostic platform.

　　Through a collaborative effort with National Cheng Kung University and multiple academic research institutions, Caduceus Biotechnology Inc. has successfully developed an innovative Lab-in-a-Vial (LV) platform based on its proprietary Point-of-Care Testing (POCT) device. This platform leverages digital enzyme-linked immunosorbent assay (dELISA) technology, employing microfluidic techniques to concentrate samples and facilitate reactions. Within a mere 15 minutes, the platform can quantitatively detect biomarkers. The high sensitivity and high throughput of dELISA, combined with the rapid and convenient nature of POCT, make this platform highly promising for clinical applications. Moreover, the platform's integration with a network enables remote data transmission and analysis, contributing to the establishment of more comprehensive disease management systems.

Caduceus Biotechnology Inc.'s innovative POCT device graces the cover of Small journal, highlighting a significant technological advancement.

Validated for COVID-19 (IgG/IgM) and bladder cancer NMP22, the platform exhibits superior sensitivity compared to Abbott rapid tests in detecting COVID-19 using saliva samples. For bladder cancer, the platform accurately quantifies biomarkers in urine samples, demonstrating performance on par with Bio-Rad's assays. The Lab-in-a-Vial (LV) platform holds significant promise for clinical applications and research endeavors.

• If you want to know more details, you cand download the attachment

  
  

Small_2024_dELISA

.pdf

Download PDF • 2.77MB